n n n ‘. concat(e. i18n. t(“search. voice. recognition_retry”),’n
CARLSBAD, Calif. , March 12, 2024 (GLOBE NEWSWIRE) — Design Therapeutics, Inc. (Nasdaq: DSGN), a biotech company seeking remedies for serious degenerative genetic diseases, announced that the company will host a conference call and live webcast on Tuesday, March 19, 2024 at 4:30 p. m. ET to discuss its fourth quarter and full monetary effects of the year 2023 and provide a full portfolio update.
The occasion will be streamed live on the Internet in the “Events” segment of www. designtx. com’s investor page and can also be viewed here. A replay of the webcast will be archived in Design for 30 days.
Dial-in access for convention attendees can be received by registering for the occasion here.
About Design TherapeuticsDesign Therapeutics is a biotechnology company introducing a new generation of therapeutics based on its chimeric small molecule platform targeting the GeneTAC™ gene. The company’s GeneTAC™ molecules are designed to develop or minimize the expression of an express gene that causes disease. to address the underlying cause of the disease. In addition to its GeneTAC™ small molecule leader, DT-216, recently in development for patients with Friedreich’s ataxia, the company is advancing its systems on Fuchs’ corneal endothelial dystrophy and myotonic dystrophy type 1. Efforts are also underway to uncover other serious genetic disorders. For more information, visit designtx. com.
Contact:Investors:Renee LeckTHRUST Strategic Communicationsrenee@thrustsc. com